The first study analyzed TP53 mutation enrichment in early-stage versus late-stage colorectal cancer (CRC) patients, where AI-HOPE identified a significant enrichment of TP53 mutations in late-stage (III/IV) CRC compared to early-stage (I/II) cases. This evidence concerns the gene TP53 and colorectal cancer.